Key findings include: The trial met its secondary effectiveness endpoint – defined as the occurrence of ischemic stroke or systemic embolism over 24 months – with a rate of 3.4% compared to the performance goal of 8.7%. No patients experienced a device embolization or pericardial effusion requiring cardiac surgery through 24 months.